Below are the most recent publications written about "Radiation Tolerance" by people in Profiles.
-
Calderon-Aparicio A, He J, Simone NL. S6K1 Controls DNA Damage Signaling Modulated by the MRN Complex to Induce Radioresistance in Lung Cancer. Int J Mol Sci. 2024 Sep 28; 25(19).
-
Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G. PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination. Int J Mol Sci. 2022 Oct 25; 23(21).
-
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787.
-
Nikolakopoulou A, Soni A, Habibi M, Karaiskos P, Pantelias G, Terzoudi GI, Iliakis G. G2/M Checkpoint Abrogation With Selective Inhibitors Results in Increased Chromatid Breaks and Radiosensitization of 82-6 hTERT and RPE Human Cells. Front Public Health. 2021; 9:675095.
-
Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 12 01; 111(12):1339-1349.
-
Pompsch M, Vogel J, Classen F, Kranz P, Iliakis G, Riffkin H, Brockmeier U, Metzen E. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia. BMC Cancer. 2018 Nov 29; 18(1):1190.
-
Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019 01; 106:61-68.
-
Soni A, Li F, Wang Y, Grabos M, Krieger LM, Chaudhary S, Hasan MSM, Ahmed M, Coleman CN, Teicher BA, Piekarz RL, Wang D, Iliakis GE. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks. Mol Cancer Ther. 2018 10; 17(10):2206-2216.
-
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372.
-
Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol. 2017 Aug 10; 35(23):2692-2699.